Detectable prostate‐specific antigen after radiotherapy for clinically localized prostate cancer
Cancer · 15.08.2025 · 131 (16)
DOI: 10.1002/cncr.70045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 17.08.2025. Verfasst von Ugo Giovanni Falagario und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Kidney Transplantation, University of Foggia, Foggia, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Association of Urology.
Abstract (Originalsprache)
Background
This study assesses the incidence and timing of undetectable prostate‐specific antigen (PSA) after radiotherapy (RT) ± androgen deprivation therapy (ADT) and its association with prostate cancer mortality.
Methods
This is a population‐based study including 5299 men undergoing RT (2006–2020) in the Stockholm County, Sweden with all their PSA tests until death or emigration. The authors calculated incidence and timing of undetectable PSA (PSA ≤0.1 ng/mL) and used competing risk regression to evaluate the association of detectable PSA at 6 and 12 months with prostate cancer mortality (PCSM).
Results
Median follow‐up for survivors was 81 (32, 130) months. PSA nadir values were reached before 6 and 12 months in 233 (23%) and 470 (36%) patients undergoing RT and 2871 (85%) and 3612 (90%) patients undergoing RT+ADT. No significant association was found between PSA at nadir, 6 and 12 months and PCSM in the radiotherapy group and evidence of association with higher PCSM in RT+ADT group (PSA at nadir: subdistribution hazard ratio [sHR], 2.23 [2.01–2.49]; PSA at 6 months: sHR, 6.91 [5.17–9.23]; and PSA at 12 months: sHR, 37.9 [23.0–62.5]). At 12 years after RT + ADT, PCSM rates were 27%, 15%, 13%, and 5% for patients with PSA at 6 months of ≥0.5, 0.2–0.5, 0.1–0.2, and ≤0.1 ng/mL, respectively; corresponding rates by PSA at 12 months were 34%, 18%, 12%, and 5%.
Conclusions
Most patients undergoing RT+ADT reached a PSA ≤0.1 ng/mL within 6 and 12 months. PSA>0.1 ng/mL at these time points indicated a higher risk of PCSM, emphasizing the need for timely restaging and intensified salvage treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Kidney Transplantation, University of Foggia, Foggia, Italy.
- Department of Molecular Medicine and Surgery, (Solna), Karolinska Institutet, Stockholm, Sweden.
- Unit of Urology/Division of Oncology, Soldera Prostate Cancer Lab, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy.
- Departments of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Department of Oncology, St. Göran Hospital, Stockholm, Sweden.
ORCID-Profile: Alexander Valdman
Förderung
- European Association of Urology
Zitieren
APA
Falagario, U. G., Pellegrino, F., Abbadi, A., Björnebo, L., Valdman, A., Eriksson, M. H., Zelic, R., Carrieri, G., Gandaglia, G., Briganti, A., Montorsi, F., Aly, M., Palsdottir, T., Eklund, M., Nordström, T., Grönberg, H., Akre, O., Wiklund, P., & Lantz, A. (2025). Detectable prostate‐specific antigen after radiotherapy for clinically localized prostate cancer. Cancer, 131(16). https://doi.org/10.1002/cncr.70045
Vancouver
Falagario UG, Pellegrino F, Abbadi A, Björnebo L, Valdman A, Eriksson MH, et al. Detectable prostate‐specific antigen after radiotherapy for clinically localized prostate cancer. Cancer. 2025;131(16). doi:10.1002/cncr.70045
BibTeX
@article{Falagario2025,
author = {Falagario, Ugo Giovanni and Pellegrino, Francesco and Abbadi, Ahmad and Björnebo, Lars and Valdman, Alexander and Eriksson, Marie Hjelm and Zelic, Renata and Carrieri, Giuseppe and Gandaglia, Giorgio and Briganti, Alberto and Montorsi, Francesco and Aly, Markus and Palsdottir, Thorgerdur and Eklund, Martin and Nordström, Tobias and Grönberg, Henrik and Akre, Olof and Wiklund, Peter and Lantz, Anna},
title = {Detectable prostate‐specific antigen after radiotherapy for clinically localized prostate cancer},
journal = {Cancer},
year = {2025},
volume = {131},
number = {16},
doi = {10.1002/cncr.70045}
}
EUVIMED